von Redaktion LCGC | Jul 2, 2015
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl...
von Redaktion LCGC | Jun 10, 2015
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. Scheffler M,...
von Redaktion LCGC | Apr 30, 2015
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian...
von Redaktion LCGC | Mrz 20, 2015
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière...
von Redaktion LCGC | Mrz 16, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ,...